

Clinical Policy Title:	duvelisib
Policy Number:	RxA.360
Drug(s) Applied:	Copiktra®
Original Policy Date:	03/06/2020
Last Review Date:	12/11/2025
Line of Business Policy Applies to:	All lines of business (except Medicare)

Criteria

I. Initial Approval Criteria

A. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (must meet all):

1. Diagnosis of relapsed or refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma;
2. Prescribed by or in consultation with an oncologist or a hematologist;
3. Relapsed/refractory disease after at least two prior therapies;
*Prior authorization may be required.
4. Prescribed as a single agent;

Approval duration

All lines of business (except Medicare): 12 months, Split-fill

B. T-Cell Lymphomas (off-label) (must meet all):

1. Diagnosis is one of the following (a, b or c):
 - a. Hepatosplenic T-Cell Lymphoma after 2 first-line therapy regimens;
 - b. Breast Implant-Associated ALCL after at least one prior therapy;
 - c. Peripheral T-Cell Lymphomas in one of the following settings (i or ii):
 - i. Initial palliative intent therapy;
 - ii. After at least one prior therapy;
2. Prescribed as a single agent for relapsed/refractory disease;

Approval duration

All lines of business (except Medicare): 12 months, Split-fill

II. Continued Therapy Approval

A. All Indications in Section I (must meet all):

1. Auto-approval based on lookback functionality within the past 120 days as a proxy for member responding positively to therapy.

Approval duration

All lines of business (except Medicare): 12 months

References

1. National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed June 12, 2024.

This clinical policy has been developed to authorize, modify, or determine coverage for individuals with similar conditions. Specific care and treatment may vary depending on individual need and benefits covered by the plan. This policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. This document may contain prescription brand name drugs that are trademarks of pharmaceutical manufacturers that are not affiliated with RxAdvance.

Review/Revision History	Review/Revised Date	P&T Approval Date
Policy established.	01/2020	03/06/2020
Policy was reviewed: <ol style="list-style-type: none"> 1. Policy title table was updated. 2. Line of Business Policy Applies to was update to all lines of business. 3. Initial and Continued Approval Duration: Commercial approval duration was updated from 'length of benefit' to '6 months'. 4. Continued Therapy criteria II.A.1 was rephrased to "Currently receiving medication that has been authorized by RxAdvance..." 5. References were updated. 	08/02/2020	09/14/2020
Policy was reviewed. <ol style="list-style-type: none"> 1. Initial Approval Criteria and Continued Therapy Approval Criteria were updated to remove HIM approval duration. 2. Initial Approval Criteria IA.4 was updated from "Relapsed/refractory disease after at least one prior therapy" to "Relapsed/refractory disease after at least two prior therapies..." 3. References were reviewed and updated. 	06/02/2021	09/14/2021
Policy was reviewed. <ol style="list-style-type: none"> 1. Initial Approval Criteria, I.B: Updated to remove approval criteria for Follicular and Marginal Zone Lymphomas. 2. Initial Approval Criteria, I.B: Updated to include approval criteria for indication, T-Cell Lymphomas (off-label). 3. References were reviewed and updated. 	03/17/2022	07/18/2022
Policy was reviewed: <ol style="list-style-type: none"> 1. Initial Approval Criteria, I.A.5: Updated to include new prescribing criteria Prescribed as a single agent. 2. Initial Approval Criteria I.A and I.B: Commercial approval duration updated from 6 months to 12 months. 3. Continued therapy approval criteria II.A: Commercial and Medicaid duration updated from 6 months to 12 months. 4. Initial Approval Criteria, I.B.1.a, I.B.1.b and I.B.1.c: Updated diagnostic criteria from Diagnosis is one of the following (a, b or c): <ol style="list-style-type: none"> a. Hepatosplenic T-Cell Lymphoma; b. Breast Implant-Associated ALCL; 	4/14/2023	7/13/2023

Review/Revision History	Review/Revised Date	P&T Approval Date
<ul style="list-style-type: none"> c. Peripheral T-Cell Lymphomas to Diagnosis is one of the following (a, b or c): <ul style="list-style-type: none"> a. Hepatosplenic T-Cell Lymphoma after 2 first-line therapy regimens; b. Breast Implant-Associated ALCL after at least one prior therapy; c. Peripheral T-Cell Lymphomas in one of the following settings (i or ii): <ul style="list-style-type: none"> i. Initial palliative intent therapy; ii. After at least one prior therapy. 5. Initial Approval Criteria, I.B.3: Updated to include new age criteria Age ≥ 18 years. 6. Continued Therapy Approval, II.A.3.b: Updated to include new dosing criteria Dose does not exceed 80 mg per day if co-administered with a moderate CYP3A4 inducer. 7. References were reviewed and updated. 		
Policy was reviewed.	10/19/2023	10/19/2023
Policy was reviewed: <ul style="list-style-type: none"> 1. Age Criteria Removed. 2. Dose Criteria Removed. 3. Approval Duration Updated. 4. Continuation Criteria Updated. 5. References were reviewed and updated. 	6/12/2024	6/12/2024
Policy was reviewed.	12/05/2024	N/A
Policy was reviewed.	12/11/2025	12/11/2025